310 results on '"Brenner, Hermann"'
Search Results
2. Genome-wide interaction analysis of folate for colorectal cancer risk.
- Author
-
Bouras, Emmanouil, Kim, Andre, Lin, Yi, Morrison, John, Du, Mengmeng, Albanes, Demetrius, Barry, Elizabeth, Baurley, James, Berndt, Sonja, Bien, Stephanie, Bishop, Timothy, Brenner, Hermann, Budiarto, Arif, Burnett-Hartman, Andrea, Campbell, Peter, Carreras-Torres, Robert, Casey, Graham, Cenggoro, Tjeng, Chan, Andrew, Chang-Claude, Jenny, Conti, David, Cotterchio, Michelle, Devall, Matthew, Diez-Obrero, Virginia, Dimou, Niki, Drew, David, Figueiredo, Jane, Giles, Graham, Gruber, Stephen, Gunter, Marc, Harrison, Tabitha, Hidaka, Akihisa, Hoffmeister, Michael, Huyghe, Jeroen, Joshi, Amit, Kawaguchi, Eric, Keku, Temitope, Kundaje, Anshul, Le Marchand, Loic, Lewinger, Juan, Li, Li, Lynch, Brigid, Mahesworo, Bharuno, Männistö, Satu, Moreno, Victor, Murphy, Neil, Newcomb, Polly, Obón-Santacana, Mireia, Ose, Jennifer, Palmer, Julie, Papadimitriou, Nikos, Pardamean, Bens, Pellatt, Andrew, Peoples, Anita, Platz, Elizabeth, Potter, John, Qi, Lihong, Qu, Conghui, Rennert, Gad, Ruiz-Narvaez, Edward, Sakoda, Lori, Schmit, Stephanie, Shcherbina, Anna, Stern, Mariana, Su, Yu-Ru, Tangen, Catherine, Thomas, Duncan, Tian, Yu, Um, Caroline, van Duijnhoven, Franzel, Van Guelpen, Bethany, Visvanathan, Kala, Wang, Jun, White, Emily, Wolk, Alicja, Woods, Michael, Ulrich, Cornelia, Hsu, Li, Gauderman, W, Peters, Ulrike, and Tsilidis, Konstantinos
- Subjects
CRC ,European ,GWIS ,SYN2 ,TIMP4 ,colorectal cancer ,folate ,folic acid ,genome-wide ,interaction ,synapsin ,tissue inhibitor of metalloproteinase 4 ,Humans ,Folic Acid ,Risk Factors ,Colorectal Neoplasms ,Case-Control Studies ,Dietary Supplements - Abstract
BACKGROUND: Epidemiological and experimental evidence suggests that higher folate intake is associated with decreased colorectal cancer (CRC) risk; however, the mechanisms underlying this relationship are not fully understood. Genetic variation that may have a direct or indirect impact on folate metabolism can provide insights into folates role in CRC. OBJECTIVES: Our aim was to perform a genome-wide interaction analysis to identify genetic variants that may modify the association of folate on CRC risk. METHODS: We applied traditional case-control logistic regression, joint 3-degree of freedom, and a 2-step weighted hypothesis approach to test the interactions of common variants (allele frequency >1%) across the genome and dietary folate, folic acid supplement use, and total folate in relation to risk of CRC in 30,550 cases and 42,336 controls from 51 studies from 3 genetic consortia (CCFR, CORECT, GECCO). RESULTS: Inverse associations of dietary, total folate, and folic acid supplement with CRC were found (odds ratio [OR]: 0.93; 95% confidence interval [CI]: 0.90, 0.96; and 0.91; 95% CI: 0.89, 0.94 per quartile higher intake, and 0.82 (95% CI: 0.78, 0.88) for users compared with nonusers, respectively). Interactions (P-interaction < 5×10-8) of folic acid supplement and variants in the 3p25.2 locus (in the region of Synapsin II [SYN2]/tissue inhibitor of metalloproteinase 4 [TIMP4]) were found using traditional interaction analysis, with variant rs150924902 (located upstream to SYN2) showing the strongest interaction. In stratified analyses by rs150924902 genotypes, folate supplementation was associated with decreased CRC risk among those carrying the TT genotype (OR: 0.82; 95% CI: 0.79, 0.86) but increased CRC risk among those carrying the TA genotype (OR: 1.63; 95% CI: 1.29, 2.05), suggesting a qualitative interaction (P-interaction = 1.4×10-8). No interactions were observed for dietary and total folate. CONCLUSIONS: Variation in 3p25.2 locus may modify the association of folate supplement with CRC risk. Experimental studies and studies incorporating other relevant omics data are warranted to validate this finding.
- Published
- 2023
3. Genetically determined circulating resistin concentrations and risk of colorectal cancer: a two-sample Mendelian randomization study
- Author
-
Pham, Thu Thi, Nimptsch, Katharina, Papadimitriou, Nikos, Aleksandrova, Krasimira, Jenab, Mazda, Gunter, Marc J., Le Marchand, Loic, Li, Li, Lynch, Brigid M., Castellví-Bel, Sergi, Phipps, Amanda I., Schmit, Stephanie L., Brenner, Hermann, Ogino, Shuji, Giovannucci, Edward, and Pischon, Tobias
- Published
- 2023
- Full Text
- View/download PDF
4. When gold standards are not so golden: prevalence bias in randomized trials on endoscopic colorectal cancer screening
- Author
-
Brenner, Hermann, Heisser, Thomas, Cardoso, Rafael, and Hoffmeister, Michael
- Published
- 2023
- Full Text
- View/download PDF
5. Is the association of overweight and obesity with colorectal cancer underestimated? An umbrella review of systematic reviews and meta-analyses
- Author
-
Mandic, Marko, Li, Hengjing, Safizadeh, Fatemeh, Niedermaier, Tobias, Hoffmeister, Michael, and Brenner, Hermann
- Published
- 2023
- Full Text
- View/download PDF
6. Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study
- Author
-
Tsilidis, Konstantinos K, Papadimitriou, Nikos, Dimou, Niki, Gill, Dipender, Lewis, Sarah J, Martin, Richard M, Murphy, Neil, Markozannes, Georgios, Zuber, Verena, Cross, Amanda J, Burrows, Kimberley, Lopez, David S, Key, Timothy J, Travis, Ruth C, Perez-Cornago, Aurora, Hunter, David J, van Duijnhoven, Fränzel JB, Albanes, Demetrius, Arndt, Volker, Berndt, Sonja I, Bézieau, Stéphane, Bishop, D Timothy, Boehm, Juergen, Brenner, Hermann, Burnett-Hartman, Andrea, Campbell, Peter T, Casey, Graham, Castellví-Bel, Sergi, Chan, Andrew T, Chang-Claude, Jenny, de la Chapelle, Albert, Figueiredo, Jane C, Gallinger, Steven J, Giles, Graham G, Goodman, Phyllis J, Gsur, Andrea, Hampe, Jochen, Hampel, Heather, Hoffmeister, Michael, Jenkins, Mark A, Keku, Temitope O, Kweon, Sun-Seog, Larsson, Susanna C, Le Marchand, Loic, Li, Christopher I, Li, Li, Lindblom, Annika, Martín, Vicente, Milne, Roger L, Moreno, Victor, Nan, Hongmei, Nassir, Rami, Newcomb, Polly A, Offit, Kenneth, Pharoah, Paul DP, Platz, Elizabeth A, Potter, John D, Qi, Lihong, Rennert, Gad, Sakoda, Lori C, Schafmayer, Clemens, Slattery, Martha L, Snetselaar, Linda, Schenk, Jeanette, Thibodeau, Stephen N, Ulrich, Cornelia M, Van Guelpen, Bethany, Harlid, Sophia, Visvanathan, Kala, Vodickova, Ludmila, Wang, Hansong, White, Emily, Wolk, Alicja, Woods, Michael O, Wu, Anna H, Zheng, Wei, Bueno-de-Mesquita, Bas, Boutron-Ruault, Marie-Christine, Hughes, David J, Jakszyn, Paula, Kühn, Tilman, Palli, Domenico, Riboli, Elio, Giovannucci, Edward L, Banbury, Barbara L, Gruber, Stephen B, Peters, Ulrike, Gunter, Marc J, and on behalf of GECCO, CORECT
- Subjects
Complementary and Integrative Health ,Digestive Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Colo-Rectal Cancer ,Prevention ,Nutrition ,Prevention of disease and conditions ,and promotion of well-being ,3.3 Nutrition and chemoprevention ,Case-Control Studies ,Colorectal Neoplasms ,Dietary Supplements ,Genetic Predisposition to Disease ,Humans ,Mendelian Randomization Analysis ,Micronutrients ,Risk Factors ,Selenium ,Vitamin B 12 ,White People ,Mendelian randomization ,genes ,nutrition ,supplements ,colorectal cancer ,Engineering ,Medical and Health Sciences ,Nutrition & Dietetics - Abstract
BackgroundThe literature on associations of circulating concentrations of minerals and vitamins with risk of colorectal cancer is limited and inconsistent. Evidence from randomized controlled trials (RCTs) to support the efficacy of dietary modification or nutrient supplementation for colorectal cancer prevention is also limited.ObjectivesTo complement observational and RCT findings, we investigated associations of genetically predicted concentrations of 11 micronutrients (β-carotene, calcium, copper, folate, iron, magnesium, phosphorus, selenium, vitamin B-6, vitamin B-12, and zinc) with colorectal cancer risk using Mendelian randomization (MR).MethodsTwo-sample MR was conducted using 58,221 individuals with colorectal cancer and 67,694 controls from the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry. Inverse variance-weighted MR analyses were performed with sensitivity analyses to assess the impact of potential violations of MR assumptions.ResultsNominally significant associations were noted for genetically predicted iron concentration and higher risk of colon cancer [ORs per SD (ORSD): 1.08; 95% CI: 1.00, 1.17; P value = 0.05] and similarly for proximal colon cancer, and for vitamin B-12 concentration and higher risk of colorectal cancer (ORSD: 1.12; 95% CI: 1.03, 1.21; P value = 0.01) and similarly for colon cancer. A nominally significant association was also noted for genetically predicted selenium concentration and lower risk of colon cancer (ORSD: 0.98; 95% CI: 0.96, 1.00; P value = 0.05) and similarly for distal colon cancer. These associations were robust to sensitivity analyses. Nominally significant inverse associations were observed for zinc and risk of colorectal and distal colon cancers, but sensitivity analyses could not be performed. None of these findings survived correction for multiple testing. Genetically predicted concentrations of β-carotene, calcium, copper, folate, magnesium, phosphorus, and vitamin B-6 were not associated with disease risk.ConclusionsThese results suggest possible causal associations of circulating iron and vitamin B-12 (positively) and selenium (inversely) with risk of colon cancer.
- Published
- 2021
7. Quality of life, distress, and posttraumatic growth 5 years after colorectal cancer diagnosis according to history of inpatient rehabilitation
- Author
-
Scherer-Trame, Sophie, Jansen, Lina, Koch-Gallenkamp, Lena, Arndt, Volker, Chang-Claude, Jenny, Hoffmeister, Michael, and Brenner, Hermann
- Published
- 2022
- Full Text
- View/download PDF
8. Functional informed genome‐wide interaction analysis of body mass index, diabetes and colorectal cancer risk
- Author
-
Xia, Zhiyu, Su, Yu‐Ru, Petersen, Paneen, Qi, Lihong, Kim, Andre E, Figueiredo, Jane C, Lin, Yi, Nan, Hongmei, Sakoda, Lori C, Albanes, Demetrius, Berndt, Sonja I, Bézieau, Stéphane, Bien, Stephanie, Buchanan, Daniel D, Casey, Graham, Chan, Andrew T, Conti, David V, Drew, David A, Gallinger, Steven J, Gauderman, W James, Giles, Graham G, Gruber, Stephen B, Gunter, Marc J, Hoffmeister, Michael, Jenkins, Mark A, Joshi, Amit D, Le Marchand, Loic, Lewinger, Juan P, Li, Li, Lindor, Noralane M, Moreno, Victor, Murphy, Neil, Nassir, Rami, Newcomb, Polly A, Ogino, Shuji, Rennert, Gad, Song, Mingyang, Wang, Xiaoliang, Wolk, Alicja, Woods, Michael O, Brenner, Hermann, White, Emily, Slattery, Martha L, Giovannucci, Edward L, Chang‐Claude, Jenny, Pharoah, Paul DP, Hsu, Li, Campbell, Peter T, and Peters, Ulrike
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Digestive Diseases ,Human Genome ,Genetics ,Cancer ,Diabetes ,Prevention ,Nutrition ,Colo-Rectal Cancer ,Metabolic and endocrine ,ATPases Associated with Diverse Cellular Activities ,Aged ,Body Mass Index ,Colorectal Neoplasms ,Databases ,Genetic ,Diabetes Mellitus ,Type 2 ,Female ,Gene Expression ,Genotype ,Hepatocyte Nuclear Factor 3-alpha ,Humans ,Male ,Microtubule-Associated Proteins ,Middle Aged ,Obesity ,Phenotype ,Proteasome Endopeptidase Complex ,Protein Tyrosine Phosphatase ,Non-Receptor Type 2 ,Sex Factors ,Sialic Acid Binding Ig-like Lectin 3 ,Voltage-Gated Sodium Channel beta-1 Subunit ,BMI ,colorectal cancer ,diabetes ,gene expression ,gene-environmental interaction ,Biochemistry and Cell Biology ,Oncology and carcinogenesis - Abstract
BackgroundBody mass index (BMI) and diabetes are established risk factors for colorectal cancer (CRC), likely through perturbations in metabolic traits (e.g. insulin resistance and glucose homeostasis). Identification of interactions between variation in genes and these metabolic risk factors may identify novel biologic insights into CRC etiology.MethodsTo improve statistical power and interpretation for gene-environment interaction (G × E) testing, we tested genetic variants that regulate expression of a gene together for interaction with BMI (kg/m2 ) and diabetes on CRC risk among 26 017 cases and 20 692 controls. Each variant was weighted based on PrediXcan analysis of gene expression data from colon tissue generated in the Genotype-Tissue Expression Project for all genes with heritability ≥1%. We used a mixed-effects model to jointly measure the G × E interaction in a gene by partitioning the interactions into the predicted gene expression levels (fixed effects), and residual G × E effects (random effects). G × BMI analyses were stratified by sex as BMI-CRC associations differ by sex. We used false discovery rates to account for multiple comparisons and reported all results with FDR
- Published
- 2020
9. Regression-based Deep-Learning predicts molecular biomarkers from pathology slides.
- Author
-
El Nahhas, Omar S. M., Loeffler, Chiara M. L., Carrero, Zunamys I., van Treeck, Marko, Kolbinger, Fiona R., Hewitt, Katherine J., Muti, Hannah S., Graziani, Mara, Zeng, Qinghe, Calderaro, Julien, Ortiz-Brüchle, Nadina, Yuan, Tanwei, Hoffmeister, Michael, Brenner, Hermann, Brobeil, Alexander, Reis-Filho, Jorge S., and Kather, Jakob Nikolas
- Subjects
TUMOR markers ,HOMOLOGOUS recombination ,DEEP learning ,BIOMARKERS ,COLORECTAL cancer - Abstract
Deep Learning (DL) can predict biomarkers from cancer histopathology. Several clinically approved applications use this technology. Most approaches, however, predict categorical labels, whereas biomarkers are often continuous measurements. We hypothesize that regression-based DL outperforms classification-based DL. Therefore, we develop and evaluate a self-supervised attention-based weakly supervised regression method that predicts continuous biomarkers directly from 11,671 images of patients across nine cancer types. We test our method for multiple clinically and biologically relevant biomarkers: homologous recombination deficiency score, a clinically used pan-cancer biomarker, as well as markers of key biological processes in the tumor microenvironment. Using regression significantly enhances the accuracy of biomarker prediction, while also improving the predictions' correspondence to regions of known clinical relevance over classification. In a large cohort of colorectal cancer patients, regression-based prediction scores provide a higher prognostic value than classification-based scores. Our open-source regression approach offers a promising alternative for continuous biomarker analysis in computational pathology. Cancer biomarkers are often continuous measurements, which poses challenges for their prediction using classification-based deep learning. Here, the authors develop a regression-based deep learning method to predict continuous biomarkers - such as the homologous repair deficiency score - from cancer histopathology images. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood.
- Author
-
Fan, Ziwen, Edelmann, Dominic, Yuan, Tanwei, Köhler, Bruno Christian, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
EPIGENOMICS ,DNA methylation ,COLORECTAL cancer ,PREDICTION models ,GENOME-wide association studies ,BLOOD collection - Abstract
While genome-wide association studies are valuable in identifying CRC survival predictors, the benefit of adding blood DNA methylation (blood-DNAm) to clinical features, including the TNM system, remains unclear. In a multi-site population-based patient cohort study of 2116 CRC patients with baseline blood-DNAm, we analyzed survival predictions using eXtreme Gradient Boosting with a 5-fold nested leave-sites-out cross-validation across four groups: traditional and comprehensive clinical features, blood-DNAm, and their combination. Model performance was assessed using time-dependent ROC curves and calibrations. During a median follow-up of 10.3 years, 1166 patients died. Although blood-DNAm-based predictive signatures achieved moderate performances, predictive signatures based on clinical features outperformed blood-DNAm signatures. The inclusion of blood-DNAm did not improve survival prediction over clinical features. M1 stage, age at blood collection, and N2 stage were the top contributors. Despite some prognostic value, incorporating blood DNA methylation did not enhance survival prediction of CRC patients beyond clinical features. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Wirksamkeit von Screeningprogrammen: Darmkrebsfrüherkennung
- Author
-
Brenner, Hermann and Hoffmeister, Michael
- Published
- 2022
- Full Text
- View/download PDF
12. Cancer‐specific risk prediction with a serum microRNA signature.
- Author
-
Raut, Janhavi R., Bhardwaj, Megha, Schöttker, Ben, Holleczek, Bernd, Schrotz‐King, Petra, and Brenner, Hermann
- Abstract
We recently derived and validated a serum‐based microRNA risk score (miR‐score) that predicted colorectal cancer (CRC) occurrence with very high accuracy within 14 years of follow‐up in a population‐based cohort study from Germany (ESTHER cohort). Here, we aimed to evaluate associations of the CRC‐specific miR‐score with the risk of developing other common cancers, including female breast cancer (BC), lung cancer (LC), and prostate cancer (PC), in the ESTHER cohort. MicroRNAs (miRNAs) were profiled by quantitative real‐time PCR in serum samples collected at baseline from randomly selected incident cases of BC (n = 90), LC (n = 88), and PC (n = 93) and participants without diagnosis of CRC, LC, BC, or PC (controls, n = 181) until the end of the 17‐year follow‐up. Multivariate logistic regression models were used to evaluate the associations of the miR‐score with BC, LC, and PC incidence. The miR‐score showed strong inverse associations with BC and LC incidence [odds ratio per 1 standard deviation increase: 0.60 (95% confidence interval [CI] 0.43–0.82), p = 0.0017, and 0.64 (95% CI 0.48–0.84),p = 0.0015, respectively]. Associations with PC were not statistically significant but pointed in the positive direction. Our study highlights the potential of serum‐based miRNA biomarkers for cancer‐specific risk prediction. Further large cohort studies aiming to investigate, validate, and optimize the use of circulating miRNA signatures for cancer risk assessment are warranted. Circulating microRNAs (miRNAs) could improve cancer risk prediction. Our findings demonstrate that miRNA profiles associated with tumor progression differ across cancer types and could be useful for developing personalized cancer prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Automated curation of large‐scale cancer histopathology image datasets using deep learning.
- Author
-
Hilgers, Lars, Ghaffari Laleh, Narmin, West, Nicholas P, Westwood, Alice, Hewitt, Katherine J, Quirke, Philip, Grabsch, Heike I, Carrero, Zunamys I, Matthaei, Emylou, Loeffler, Chiara M L, Brinker, Titus J, Yuan, Tanwei, Brenner, Hermann, Brobeil, Alexander, Hoffmeister, Michael, and Kather, Jakob Nikolas
- Subjects
DEEP learning ,ARTIFICIAL neural networks ,CONVOLUTIONAL neural networks ,HISTOPATHOLOGY ,ARTIFICIAL intelligence ,COLORECTAL cancer - Abstract
Background: Artificial intelligence (AI) has numerous applications in pathology, supporting diagnosis and prognostication in cancer. However, most AI models are trained on highly selected data, typically one tissue slide per patient. In reality, especially for large surgical resection specimens, dozens of slides can be available for each patient. Manually sorting and labelling whole‐slide images (WSIs) is a very time‐consuming process, hindering the direct application of AI on the collected tissue samples from large cohorts. In this study we addressed this issue by developing a deep‐learning (DL)‐based method for automatic curation of large pathology datasets with several slides per patient. Methods: We collected multiple large multicentric datasets of colorectal cancer histopathological slides from the United Kingdom (FOXTROT, N = 21,384 slides; CR07, N = 7985 slides) and Germany (DACHS, N = 3606 slides). These datasets contained multiple types of tissue slides, including bowel resection specimens, endoscopic biopsies, lymph node resections, immunohistochemistry‐stained slides, and tissue microarrays. We developed, trained, and tested a deep convolutional neural network model to predict the type of slide from the slide overview (thumbnail) image. The primary statistical endpoint was the macro‐averaged area under the receiver operating curve (AUROCs) for detection of the type of slide. Results: In the primary dataset (FOXTROT), with an AUROC of 0.995 [95% confidence interval [CI]: 0.994–0.996] the algorithm achieved a high classification performance and was able to accurately predict the type of slide from the thumbnail image alone. In the two external test cohorts (CR07, DACHS) AUROCs of 0.982 [95% CI: 0.979–0.985] and 0.875 [95% CI: 0.864–0.887] were observed, which indicates the generalizability of the trained model on unseen datasets. With a confidence threshold of 0.95, the model reached an accuracy of 94.6% (7331 classified cases) in CR07 and 85.1% (2752 classified cases) for the DACHS cohort. Conclusion: Our findings show that using the low‐resolution thumbnail image is sufficient to accurately classify the type of slide in digital pathology. This can support researchers to make the vast resource of existing pathology archives accessible to modern AI models with only minimal manual annotations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Identification of potential mediators of the relationship between body mass index and colorectal cancer: a Mendelian randomization analysis.
- Author
-
Bouras, Emmanouil, Gill, Dipender, Zuber, Verena, Murphy, Neil, Dimou, Niki, Aleksandrova, Krasimira, Lewis, Sarah J, Martin, Richard M, Yarmolinsky, James, Albanes, Demetrius, Brenner, Hermann, Castellví-Bel, Sergi, Chan, Andrew T, Cheng, Iona, Gruber, Stephen, Guelpen, Bethany Van, Li, Christopher I, Marchand, Loic Le, Newcomb, Polly A, and Ogino, Shuji
- Subjects
BODY mass index ,ADIPOKINES ,COLORECTAL cancer ,SOMATOMEDIN C ,LDL cholesterol ,IRINOTECAN - Abstract
Background Colorectal cancer (CRC) is the third-most-common cancer worldwide and its rates are increasing. Elevated body mass index (BMI) is an established risk factor for CRC, although the molecular mechanisms behind this association remain unclear. Using the Mendelian randomization (MR) framework, we aimed to investigate the mediating effects of putative biomarkers and other CRC risk factors in the association between BMI and CRC. Methods We selected as mediators biomarkers of established cancer-related mechanisms and other CRC risk factors for which a plausible association with obesity exists, such as inflammatory biomarkers, glucose homeostasis traits, lipids, adipokines, insulin-like growth factor 1 (IGF1), sex hormones, 25-hydroxy-vitamin D, smoking, physical activity (PA) and alcohol consumption. We used inverse-variance weighted MR in the main univariable analyses and performed sensitivity analyses (weighted-median, MR–Egger, Contamination Mixture). We used multivariable MR for the mediation analyses. Results Genetically predicted BMI was positively associated with CRC risk [odds ratio per SD (5 kg/m
2 ) = 1.17, 95% CI: 1.08–1.24, P -value = 1.4 × 10−5 ] and robustly associated with nearly all potential mediators. Genetically predicted IGF1, fasting insulin, low-density lipoprotein cholesterol, smoking, PA and alcohol were associated with CRC risk. Evidence for attenuation was found for IGF1 [explained 7% (95% CI: 2–13%) of the association], smoking (31%, 4–57%) and PA (7%, 2–11%). There was little evidence for pleiotropy, although smoking was bidirectionally associated with BMI and instruments were weak for PA. Conclusions The effect of BMI on CRC risk is possibly partly mediated through plasma IGF1, whereas the attenuation of the BMI–CRC association by smoking and PA may reflect confounding and shared underlying mechanisms rather than mediation. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
15. Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology.
- Author
-
Gustav, Marco, Reitsam, Nic Gabriel, Carrero, Zunamys I., Loeffler, Chiara M. L., van Treeck, Marko, Yuan, Tanwei, West, Nicholas P., Quirke, Philip, Brinker, Titus J., Brenner, Hermann, Favre, Loëtitia, Märkl, Bruno, Stenzinger, Albrecht, Brobeil, Alexander, Hoffmeister, Michael, Calderaro, Julien, Pujals, Anaïs, and Kather, Jakob Nikolas
- Subjects
DEEP learning ,DNA mismatch repair ,COLORECTAL cancer ,MICROSATELLITE repeats ,DNA polymerases ,COLON tumors ,HEREDITARY nonpolyposis colorectal cancer - Abstract
In the spectrum of colorectal tumors, microsatellite-stable (MSS) tumors with DNA polymerase ε (POLE) mutations exhibit a hypermutated profile, holding the potential to respond to immunotherapy similarly to their microsatellite-instable (MSI) counterparts. Yet, due to their rarity and the associated testing costs, systematic screening for these mutations is not commonly pursued. Notably, the histopathological phenotype resulting from POLE mutations is theorized to resemble that of MSI. This resemblance not only could facilitate their detection by a transformer-based Deep Learning (DL) system trained on MSI pathology slides, but also indicates the possibility for MSS patients with POLE mutations to access enhanced treatment options, which might otherwise be overlooked. To harness this potential, we trained a Deep Learning classifier on a large dataset with the ground truth for microsatellite status and subsequently validated its capabilities for MSI and POLE detection across three external cohorts. Our model accurately identified MSI status in both the internal and external resection cohorts using pathology images alone. Notably, with a classification threshold of 0.5, over 75% of POLE driver mutant patients in the external resection cohorts were flagged as "positive" by a DL system trained on MSI status. In a clinical setting, deploying this DL model as a preliminary screening tool could facilitate the efficient identification of clinically relevant MSI and POLE mutations in colorectal tumors, in one go. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival.
- Author
-
Nikitina, Ekaterina, Burk‐Körner, Amelie, Wiesenfarth, Manuel, Alwers, Elizabeth, Heide, Danijela, Tessmer, Claudia, Ernst, Claudia, Krunic, Damir, Schrotz‐King, Petra, Chang‐Claude, Jenny, von Winterfeld, Moritz, Herpel, Esther, Brobeil, Alexander, Brenner, Hermann, Heikenwalder, Mathias, Hoffmeister, Michael, Kopp‐Schneider, Annette, and Bund, Timo
- Abstract
Bovine milk and meat factors (BMMFs) are plasmid‐like DNA molecules isolated from bovine milk and serum, as well as the peritumor of colorectal cancer (CRC) patients. BMMFs have been proposed as zoonotic infectious agents and drivers of indirect carcinogenesis of CRC, inducing chronic tissue inflammation, radical formation and increased levels of DNA damage. Data on expression of BMMFs in large clinical cohorts to test an association with co‐markers and clinical parameters were not previously available and were therefore assessed in this study. Tissue sections with paired tumor‐adjacent mucosa and tumor tissues of CRC patients [individual cohorts and tissue microarrays (TMAs) (n = 246)], low‐/high‐grade dysplasia (LGD/HGD) and mucosa of healthy donors were used for immunohistochemical quantification of the expression of BMMF replication protein (Rep) and CD68/CD163 (macrophages) by co‐immunofluorescence microscopy and immunohistochemical scoring (TMA). Rep was expressed in the tumor‐adjacent mucosa of 99% of CRC patients (TMA), was histologically associated with CD68+/CD163+ macrophages and was increased in CRC patients when compared to healthy controls. Tumor tissues showed only low stromal Rep expression. Rep was expressed in LGD and less in HGD but was strongly expressed in LGD/HGD‐adjacent tissues. Albeit not reaching statistical significance, incidence curves for CRC‐specific death were increased for higher Rep expression (TMA), with high tumor‐adjacent Rep expression being linked to the highest incidence of death. BMMF Rep expression might represent a marker and early risk factor for CRC. The correlation between Rep and CD68 expression supports a previous hypothesis that BMMF‐specific inflammatory regulations, including macrophages, are involved in the pathogenesis of CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Making the best use of quantitative fecal immunochemical test results in colorectal cancer screening.
- Author
-
Brenner, Hermann and Hoffmeister, Michael
- Subjects
- *
EARLY detection of cancer , *COLORECTAL cancer - Abstract
Fecal immunochemical tests (FITs) are widely used for colorectal cancer (CRC) screening. They can detect most CRCs and some precancerous neoplasms, and studies suggest that FIT-based screening programs can reduce the burden of CRC. A recent study in Sweden provides valuable information on the tradeoffs between increasing the positive predictive value (PPV) and decreasing the numbers needed to undergo colonoscopy (NNS) when adjusting the FIT positivity threshold. However, there are additional factors to consider, such as the use of one or two FITs per screening round and the impact of subsequent screening rounds and different starting ages. The study also addresses the question of how sex differences in CRC epidemiology and screening test performance should be considered in interpreting FIT results. The authors suggest that lower cutoffs for men could achieve equal PPVs and NNS for both sexes, but this approach may result in a lower chance of early detection or prevention for women. The study could not address the lack of colonoscopy results for participants with fecal Hb concentrations below 10 μg Hb/g feces, but other studies suggest that even individuals in the "low positive range" have a higher risk of carrying advanced neoplasms. The ultimate goal of CRC screening is to reduce incidence and mortality, and well-designed modeling studies, along with data on FIT performance and screening colonoscopy cohorts, can inform the evaluation of screening strategies. The authors have no conflicts of interest, and [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
18. Indications of sustained delay of colorectal cancer diagnoses in Germany during the first 2 years of the COVID‐19 pandemic.
- Author
-
Brenner, Hermann, Weber, Lisa, Cardoso, Rafael, Heisser, Thomas, Hoffmeister, Michael, and Holleczek, Bernd
- Subjects
COVID-19 pandemic ,COLORECTAL cancer ,CANCER diagnosis - Abstract
A study conducted in Germany analyzed the impact of the COVID-19 pandemic on the diagnosis of colorectal cancer (CRC). The study found that there were significant delays in CRC diagnoses during the first two years of the pandemic, resulting in a lower number of cases than expected. The largest discrepancy was observed in the second quarter of 2020. Although case numbers seemed to return to expected values in the later quarters of 2021, there is still a need to address the sustained delay in diagnoses. These findings are consistent with previous reports on the impact of the pandemic on CRC diagnoses and treatment in Germany. Efforts should be made to minimize such delays in the future. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
19. Circulating white blood cell traits and colorectal cancer risk: A Mendelian randomisation study.
- Author
-
Constantinescu, Andrei‐Emil, Bull, Caroline J., Jones, Nicholas, Mitchell, Ruth, Burrows, Kimberley, Dimou, Niki, Bézieau, Stéphane, Brenner, Hermann, Buchanan, Daniel D., D'Amato, Mauro, Jenkins, Mark A., Moreno, Victor, Pai, Rish K., Um, Caroline Y., White, Emily, Murphy, Neil, Gunter, Marc, Timpson, Nicholas J., Huyghe, Jeroen R., and Vincent, Emma E.
- Subjects
LEUCOCYTES ,COLORECTAL cancer ,DISEASE risk factors ,BLOOD cells ,EOSINOPHILS ,HEREDITARY nonpolyposis colorectal cancer - Abstract
Observational studies have suggested a protective role for eosinophils in colorectal cancer (CRC) development and implicated neutrophils, but the causal relationships remain unclear. Here, we aimed to estimate the causal effect of circulating white blood cell (WBC) counts (N = ~550 000) for basophils, eosinophils, monocytes, lymphocytes and neutrophils on CRC risk (N = 52 775 cases and 45 940 controls) using Mendelian randomisation (MR). For comparison, we also examined this relationship using individual‐level data from UK Biobank (4043 incident CRC cases and 332 773 controls) in a longitudinal cohort analysis. The inverse‐variance weighted (IVW) MR analysis suggested a protective effect of increased basophil count and eosinophil count on CRC risk [OR per 1‐SD increase: 0.88, 95% CI: 0.78‐0.99, P =.04; OR: 0.93, 95% CI: 0.88‐0.98, P =.01]. The protective effect of eosinophils remained [OR per 1‐SD increase: 0.88, 95% CI: 0.80‐0.97, P =.01] following adjustments for all other WBC subtypes, to account for genetic correlation between the traits, using multivariable MR. A protective effect of increased lymphocyte count on CRC risk was also found [OR: 0.84, 95% CI: 0.76‐0.93, P = 6.70e‐4] following adjustment. Consistent with MR results, a protective effect for eosinophils in the cohort analysis in the fully adjusted model [RR per 1‐SD increase: 0.96, 95% CI: 0.93‐0.99, P =.02] and following adjustment for the other WBC subtypes [RR: 0.96, 95% CI: 0.93‐0.99, P =.001] was observed. Our study implicates peripheral blood immune cells, in particular eosinophils and lymphocytes, in CRC development, highlighting a need for mechanistic studies to interrogate these relationships. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. From a Clustering of Adverse Symptoms after Colorectal Cancer Therapy to Chronic Fatigue and Low Ability to Work: A Cohort Study Analysis with 3 Months of Follow-Up.
- Author
-
Vlaski, Tomislav, Slavic, Marija, Caspari, Reiner, Bilsing, Bettine, Fischer, Harald, Brenner, Hermann, and Schöttker, Ben
- Subjects
REGRESSION analysis ,COLORECTAL cancer ,FACTOR analysis ,RESEARCH funding ,CHRONIC fatigue syndrome ,CANCER patient rehabilitation ,LONGITUDINAL method - Abstract
Simple Summary: After getting treated for colorectal cancer, many people feel fatigue, stress, and pain and face other challenges that can make daily activities and work tough. Our research explored how these issues group together and if they are connected to fatigue and difficulties in work. We gathered data from the MIRANDA study, where patients shared their experiences after colorectal cancer treatment before the start of the rehabilitation and three months after. Using data from their questionnaire responses, we identified six main problem groups: fatigue, digestive troubles, pain, feelings of stress or anxiety, urinary issues, and side effects from chemotherapy. Our findings reveal that experiencing even a single symptom from these categories can be a precursor to feeling more fatigued or having a decreased ability to work. Our findings shed light on colorectal cancer survivors' various challenges and how they might impact their daily lives and work. In colorectal cancer (CRC) patients, apart from fatigue, psychological and physical symptoms often converge, affecting their quality of life and ability to work. Our objective was to ascertain symptom clusters within a year following CRC treatment and their longitudinal association with persistent fatigue and reduced work ability at the 3-month follow-up. We used data from MIRANDA, a multicenter cohort study enrolling adult CRC patients who are starting a 3-week in-patient rehabilitation within a year post-curative CRC treatment. Participants completed questionnaires evaluating symptoms at the start of rehabilitation (baseline) and after three months. We performed an exploratory factor analysis to analyze the clustering of symptoms at baseline. Longitudinal analysis was performed using a multivariable linear regression model with dichotomized symptoms at baseline as independent variables, and the change in fatigue and ability to work from baseline to 3-month-follow-up as separate outcomes, adjusted for covariates. We identified six symptom clusters: fatigue, gastrointestinal symptoms, pain, psychosocial symptoms, urinary symptoms, and chemotherapy side effects. At least one symptom from each factor was associated with higher fatigue or reduced ability to work at the 3-month follow-up. This study highlights the interplay of multiple symptoms in influencing fatigue and work ability among CRC patients post-rehabilitation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Potential determinants of physical inactivity among long-term colorectal cancer survivors
- Author
-
Eyl, Ruth Elisa, Koch-Gallenkamp, Lena, Jansen, Lina, Walter, Viola, Carr, Prudence, Hoffmeister, Michael, Chang-Claude, Jenny, Brenner, Hermann, and Arndt, Volker
- Published
- 2018
- Full Text
- View/download PDF
22. Whole blood DNA methylation aging markers predict colorectal cancer survival: a prospective cohort study
- Author
-
Gào, Xīn, Zhang, Yan, Boakye, Daniel, Li, Xiangwei, Chang-Claude, Jenny, Hoffmeister, Michael, and Brenner, Hermann
- Published
- 2020
- Full Text
- View/download PDF
23. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study
- Author
-
Bull, Caroline J., Bell, Joshua A., Murphy, Neil, Sanderson, Eleanor, Davey Smith, George, Timpson, Nicholas J., Banbury, Barbara L., Albanes, Demetrius, Berndt, Sonja I., Bézieau, Stéphane, Bishop, D. Timothy, Brenner, Hermann, Buchanan, Daniel D., Burnett-Hartman, Andrea, Casey, Graham, Castellví-Bel, Sergi, Chan, Andrew T., Chang-Claude, Jenny, Cross, Amanda J., de la Chapelle, Albert, Figueiredo, Jane C., Gallinger, Steven J., Gapstur, Susan M., Giles, Graham G., Gruber, Stephen B., Gsur, Andrea, Hampe, Jochen, Hampel, Heather, Harrison, Tabitha A., Hoffmeister, Michael, Hsu, Li, Huang, Wen-Yi, Huyghe, Jeroen R., Jenkins, Mark A., Joshu, Corinne E., Keku, Temitope O., Kühn, Tilman, Kweon, Sun-Seog, Le Marchand, Loic, Li, Christopher I., Li, Li, Lindblom, Annika, Martín, Vicente, May, Anne M., Milne, Roger L., Moreno, Victor, Newcomb, Polly A., Offit, Kenneth, Ogino, Shuji, Phipps, Amanda I., Platz, Elizabeth A., Potter, John D., Qu, Conghui, Quirós, J. Ramón, Rennert, Gad, Riboli, Elio, Sakoda, Lori C., Schafmayer, Clemens, Schoen, Robert E., Slattery, Martha L., Tangen, Catherine M., Tsilidis, Kostas K., Ulrich, Cornelia M., van Duijnhoven, Fränzel J. B., van Guelpen, Bethany, Visvanathan, Kala, Vodicka, Pavel, Vodickova, Ludmila, Wang, Hansong, White, Emily, Wolk, Alicja, Woods, Michael O., Wu, Anna H., Campbell, Peter T., Zheng, Wei, Peters, Ulrike, Vincent, Emma E., and Gunter, Marc J.
- Published
- 2020
- Full Text
- View/download PDF
24. Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses
- Author
-
Seyed Khoei, Nazlisadat, Jenab, Mazda, Murphy, Neil, Banbury, Barbara L., Carreras-Torres, Robert, Viallon, Vivian, Kühn, Tilman, Bueno-de-Mesquita, Bas, Aleksandrova, Krasimira, Cross, Amanda J., Weiderpass, Elisabete, Stepien, Magdalena, Bulmer, Andrew, Tjønneland, Anne, Boutron-Ruault, Marie-Christine, Severi, Gianluca, Carbonnel, Franck, Katzke, Verena, Boeing, Heiner, Bergmann, Manuela M., Trichopoulou, Antonia, Karakatsani, Anna, Martimianaki, Georgia, Palli, Domenico, Tagliabue, Giovanna, Panico, Salvatore, Tumino, Rosario, Sacerdote, Carlotta, Skeie, Guri, Merino, Susana, Bonet, Catalina, Rodríguez-Barranco, Miguel, Gil, Leire, Chirlaque, Maria-Dolores, Ardanaz, Eva, Myte, Robin, Hultdin, Johan, Perez-Cornago, Aurora, Aune, Dagfinn, Tsilidis, Konstantinos K., Albanes, Demetrius, Baron, John A., Berndt, Sonja I., Bézieau, Stéphane, Brenner, Hermann, Campbell, Peter T., Casey, Graham, Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Cotterchio, Michelle, Gallinger, Steven, Gruber, Stephen B., Haile, Robert W., Hampe, Jochen, Hoffmeister, Michael, Hopper, John L., Hsu, Li, Huyghe, Jeroen R., Jenkins, Mark A., Joshi, Amit D., Kampman, Ellen, Larsson, Susanna C., Le Marchand, Loic, Li, Christopher I., Li, Li, Lindblom, Annika, Lindor, Noralane M., Martín, Vicente, Moreno, Victor, Newcomb, Polly A., Offit, Kenneth, Ogino, Shuji, Parfrey, Patrick S., Pharoah, Paul D. P., Rennert, Gad, Sakoda, Lori C., Schafmayer, Clemens, Schmit, Stephanie L., Schoen, Robert E., Slattery, Martha L., Thibodeau, Stephen N., Ulrich, Cornelia M., van Duijnhoven, Franzel J. B., Weigl, Korbinian, Weinstein, Stephanie J., White, Emily, Wolk, Alicja, Woods, Michael O., Wu, Anna H., Zhang, Xuehong, Ferrari, Pietro, Anton, Gabriele, Peters, Annette, Peters, Ulrike, Gunter, Marc J., Wagner, Karl-Heinz, and Freisling, Heinz
- Published
- 2020
- Full Text
- View/download PDF
25. Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review
- Author
-
Raut, Janhavi R., Guan, Zhong, Schrotz-King, Petra, and Brenner, Hermann
- Published
- 2020
- Full Text
- View/download PDF
26. Protocol of the VICTORIA study: personalized vitamin D supplementation for reducing or preventing fatigue and enhancing quality of life of patients with colorectal tumor - randomized intervention trial
- Author
-
Schöttker, Ben, Kuznia, Sabine, Laetsch, Dana Clarissa, Czock, David, Kopp-Schneider, Annette, Caspari, Reiner, and Brenner, Hermann
- Published
- 2020
- Full Text
- View/download PDF
27. Physical activity and long-term fatigue among colorectal cancer survivors – a population-based prospective study
- Author
-
Eyl, Ruth Elisa, Thong, Melissa S. Y., Carr, Prudence R., Jansen, Lina, Koch-Gallenkamp, Lena, Hoffmeister, Michael, Chang-Claude, Jenny, Brenner, Hermann, and Arndt, Volker
- Published
- 2020
- Full Text
- View/download PDF
28. Potential of Fecal Carcinoembryonic Antigen for Noninvasive Detection of Colorectal Cancer: A Systematic Review.
- Author
-
Li, Xianzhe, Stassen, Lara, Schrotz-King, Petra, Zhao, Zitong, Cardoso, Rafael, Raut, Janhavi R., Bhardwaj, Megha, and Brenner, Hermann
- Subjects
ONLINE information services ,SYSTEMATIC reviews ,SERUM ,CHEMILUMINESCENCE assay ,EARLY detection of cancer ,FECES ,COLORECTAL cancer ,CANCER patients ,IMMUNOASSAY ,TUMOR markers ,TUMOR antigens ,MEDLINE ,SENSITIVITY & specificity (Statistics) ,DATA analysis software - Abstract
Simple Summary: Carcinoembryonic antigen (CEA) in serum is widely used as a tumor marker in colorectal cancer (CRC). The levels of fecal CEA (FCEA) are higher than serum CEA (SCEA), especially in the early stages of CRC. In this systematic review, we aimed to provide a comprehensive overview of studies that evaluated FCEA as a biomarker for the noninvasive diagnosis and diagnosis of CRC. All of the few identified studies found statistically significant differences in FCEA levels between the CRC and control groups. Moreover, the diagnostic performance of FCEA surpassed that of SCEA, suggesting a potential role as a novel, easily measurable biomarker for the diagnosis of CRC. However, evidence is still limited to a few, mostly small, studies from clinical settings, and comprehensive evaluation in screening settings is warranted. Carcinoembryonic antigen (CEA) is more abundant in feces than in serum; however, evidence for the role of fecal CEA (FCEA) in the detection of colorectal cancer (CRC) is limited. We conducted a systematic review of studies that evaluated FCEA for the noninvasive detection and diagnosis of CRC. PubMed and Web of Science were searched for relevant studies published until 18 January 2023. Information on publication year, study design, country, study population characteristics, FCEA and serum CEA (SCEA) concentrations, and diagnostic performance was summarized. Two authors independently extracted data and assessed the risk of bias and applicability of each included study. Seven studies published between 1979 and 2021, all conducted in clinical settings and together involving 399 CRC patients and 889 controls, were identified. Significant differences in FCEA concentrations were observed between CRC and control groups in all studies. Methods for detecting FCEA varied, with the electronic chemiluminescence immunoassay (ECLIA) being used in the most recent studies. Reported sensitivities, specificities, and area under the curves of FCEA ranged from 50.0% to 85.7%, 73.0% to 100.0%, and 0.704 to 0.831, respectively. In direct comparisons, the diagnostic performance of FCEA was better than that of SCEA. The potential role of FCEA as a novel, noninvasive, easily measurable biomarker for the diagnosis of CRC requires further evaluation in screening settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.
- Author
-
Etemad, Mani, Christodoulou, Foteini, Uhlig, Stefanie, Hassel, Jessica C., Schrotz-King, Petra, Brenner, Hermann, Ulrich, Cornelia M., Bieback, Karen, Klüter, Harald, and Bugert, Peter
- Subjects
IN vitro studies ,FLOW cytometry ,PLATELET-rich plasma ,DISEASE progression ,CANCER cell culture ,MELANOMA ,WESTERN immunoblotting ,GLIOMAS ,GENE expression ,BLOOD platelet activation ,COLORECTAL cancer ,COMPARATIVE studies ,ENZYME-linked immunosorbent assay ,TUMOR markers ,BREAST tumors - Abstract
Simple Summary: Platelets express the C-type lectin-like receptor 2 (CLEC-2) that enables binding to podoplanin (PDPN)-expressing tumor cells and, thereby, promote metastatic spread. An increased level of soluble CLEC-2 was reported in patients with thromboinflammatory and malignant disease, presumably released from activated platelets. In our study, we show that in vitro platelet activation leads to a significant decrease in CLEC-2 on platelets and in the plasma. We also found decreased levels of soluble CLEC-2 in plasma samples of patients with colorectal carcinoma (stages I to IV), breast cancer or melanoma (stages I to III) compared to healthy donors. Interestingly, in patients with glioblastoma, the plasma level of soluble CLEC-2 was significantly higher. We concluded that an increased plasma level of soluble CLEC-2 is not a suitable biomarker of platelet activation and tumor progression in most types of cancer. The C-type lectin-like receptor 2 (CLEC-2) is expressed on platelets and mediates binding to podoplanin (PDPN) on various cell types. The binding to circulating tumor cells (CTCs) leads to platelet activation and promotes metastatic spread. An increased level of soluble CLEC-2 (sCLEC-2), presumably released from activated platelets, was shown in patients with thromboinflammatory and malignant disease. However, the functional role of sCLEC-2 and the mechanism of sCLEC-2 release are not known. In this study, we focused on the effect of platelet activation on CLEC-2 expression and the sCLEC-2 plasma level in patients with cancer. First, citrated blood from healthy volunteer donors (n = 20) was used to measure the effect of platelet stimulation by classical agonists and PDPN on aggregation, CLEC-2 expression on platelets with flow cytometry, sCLEC-2 release to the plasma with ELISA and total CLEC-2 expression with Western blot analysis. Second, sCLEC-2 was determined in plasma samples from healthy donors (285) and patients with colorectal carcinoma (CRC; 194), melanoma (160), breast cancer (BC; 99) or glioblastoma (49). PDPN caused a significant increase in the aggregation response induced by classical agonists. ADP or PDPN stimulation of platelets caused a significant decrease in CLEC-2 on platelets and sCLEC-2 in the plasma, whereas total CLEC-2 in platelet lysates remained the same. Thus, the increased plasma level of sCLEC-2 is not a suitable biomarker of platelet activation. In patients with CRC (median 0.9 ng/mL), melanoma (0.9 ng/mL) or BC (0.7 ng/mL), we found significantly lower sCLEC-2 levels (p < 0.0001), whereas patients with glioblastoma displayed higher levels (2.6 ng/mL; p = 0.0233) compared to healthy controls (2.1 ng/mL). The low sCLEC-2 plasma level observed in most of the tumor entities of our study presumably results from the internalization of sCLEC-2 by activated platelets or binding of sCLEC-2 to CTCs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Genome‐wide study of genetic polymorphisms predictive for outcome from first‐line oxaliplatin‐based chemotherapy in colorectal cancer patients.
- Author
-
Park, Hanla A., Edelmann, Dominic, Canzian, Federico, Seibold, Petra, Harrison, Tabitha A., Hua, Xinwei, Shi, Qian, Silverman, Allison, Benner, Axel, Macauda, Angelica, Schneider, Martin, Goldberg, Richard M., Alberts, Steven R., Hoffmeister, Michael, Brenner, Hermann, Chan, Andrew T., Peters, Ulrike, Newcomb, Polly A., and Chang‐Claude, Jenny
- Subjects
GENETIC polymorphisms ,CANCER chemotherapy ,COLORECTAL cancer ,CANCER patients ,CLINICAL trials - Abstract
We conducted the first large genome‐wide association study to identify novel genetic variants that predict better (or poorer) prognosis in colorectal cancer patients receiving standard first‐line oxaliplatin‐based chemotherapy vs chemotherapy without oxaliplatin. We used data from two phase III trials, NCCTG N0147 and NCCTG N9741 and a population‐based patient cohort, DACHS. Multivariable Cox proportional hazards models were employed, including an interaction term between each SNP and type of treatment for overall survival (OS) and progression‐free survival. The analysis was performed for studies individually, and the results were combined using fixed‐effect meta‐analyses separately for resected stage III colon cancer (3098 patients from NCCTG N0147 and 549 patients from DACHS) and mCRC (505 patients from NCCTG N9741 and 437 patients from DACHS). We further performed gene‐based analysis as well as in silico bioinformatics analysis for CRC‐relevant functional genomic annotation of identified loci. In stage III colon cancer patients, a locus on chr22 (rs11912167) was associated with significantly poorer OS after oxaliplatin‐based chemotherapy vs chemotherapy without oxaliplatin (Pinteraction < 5 × 10−8). For mCRC patients, three loci on chr1 (rs1234556), chr12 (rs11052270) and chr15 (rs11858406) were found to be associated with differential OS (P < 5 × 10−7). The locus on chr1 located in the intronic region of RCSD1 was replicated in an independent cohort of 586 mCRC patients from ALGB/SWOG 80405 (Pinteraction =.04). The GWA gene‐based analysis yielded for RCSD1 the most significant association with differential OS in mCRC (P = 6.6 × 10−6). With further investigation into its biological mechanisms, this finding could potentially be used to individualize first‐line treatment and improve clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Significant underestimation of preventive effects in colorectal cancer screening trial.
- Author
-
Heisser, Thomas, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
COLORECTAL cancer ,EARLY detection of cancer - Published
- 2024
- Full Text
- View/download PDF
32. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival
- Author
-
Jia, Min, Zhang, Yan, Jansen, Lina, Walter, Viola, Edelmann, Dominic, Gündert, Melanie, Tagscherer, Katrin E., Roth, Wilfried, Bewerunge-Hudler, Melanie, Herpel, Esther, Kloor, Matthias, Ulrich, Alexis, Burwinkel, Barbara, Bläker, Hendrik, Chang-Claude, Jenny, Brenner, Hermann, and Hoffmeister, Michael
- Published
- 2019
- Full Text
- View/download PDF
33. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS
- Author
-
Alwers, Elizabeth, Bläker, Hendrik, Walter, Viola, Jansen, Lina, Kloor, Matthias, Arnold, Alexander, Sieber-Frank, Julia, Herpel, Esther, Tagscherer, Katrin E., Roth, Wilfried, Chang-Claude, Jenny, Brenner, Hermann, and Hoffmeister, Michael
- Published
- 2019
- Full Text
- View/download PDF
34. Colorectal cancer risk stratification on histological slides based on survival curves predicted by deep learning.
- Author
-
Höhn, Julia, Krieghoff-Henning, Eva, Wies, Christoph, Kiehl, Lennard, Hetz, Martin J., Bucher, Tabea-Clara, Jonnagaddala, Jitendra, Zatloukal, Kurt, Müller, Heimo, Plass, Markus, Jungwirth, Emilian, Gaiser, Timo, Steeg, Matthias, Holland-Letz, Tim, Brenner, Hermann, Hoffmeister, Michael, and Brinker, Titus J.
- Subjects
COLORECTAL cancer ,DEEP learning ,DISEASE risk factors ,IMAGE analysis ,CANCER prognosis ,HEREDITARY nonpolyposis colorectal cancer ,AGE factors in cancer - Abstract
Studies have shown that colorectal cancer prognosis can be predicted by deep learning-based analysis of histological tissue sections of the primary tumor. So far, this has been achieved using a binary prediction. Survival curves might contain more detailed information and thus enable a more fine-grained risk prediction. Therefore, we established survival curve-based CRC survival predictors and benchmarked them against standard binary survival predictors, comparing their performance extensively on the clinical high and low risk subsets of one internal and three external cohorts. Survival curve-based risk prediction achieved a very similar risk stratification to binary risk prediction for this task. Exchanging other components of the pipeline, namely input tissue and feature extractor, had largely identical effects on model performance independently of the type of risk prediction. An ensemble of all survival curve-based models exhibited a more robust performance, as did a similar ensemble based on binary risk prediction. Patients could be further stratified within clinical risk groups. However, performance still varied across cohorts, indicating limited generalization of all investigated image analysis pipelines, whereas models using clinical data performed robustly on all cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Overall and age‐specific risk advancement periods of colorectal cancer for men vs women: Implications for gender‐sensitive screening offers?
- Author
-
Chen, Xuechen, Heisser, Thomas, Cardoso, Rafael, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
MEDICAL screening ,COLORECTAL cancer ,CANCER patients ,AGE groups ,FAMILY history (Medicine) - Abstract
Colorectal cancer (CRC) incidence and mortality are higher among men than among women. We aimed to estimate overall and age‐specific risk advancement periods (RAPs) for men compared to women, which quantify how many years earlier comparable levels of risk are reached by men. RAPs were derived by Cox regression models among 331 224 participants aged 40 to 69 at baseline of the UK Biobank with no previous diagnosis of CRC and no previous CRC screening examination who were followed with respect to CRC incidence for up to 13 years. Men were at substantially higher risk of CRC than women in age groups 50 to 59 and 60 to 69, with RAPs (95% confidence intervals) as high as 8.7 (4.5‐13.0) and 6.2 (4.5‐7.9), respectively. These RAPs were higher than those for family history of CRC in these age groups. By contrast, no significant sex difference but a major impact of family history was seen in age group 40 to 49 (P‐value for interaction between sex and age =.00079). The observed patterns suggest that consideration of gender‐specific starting ages of screening might be warranted in countries in which screening offers start at ages above 50 years. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany
- Author
-
Maalmi, Haifa, Walter, Viola, Jansen, Lina, Chang-Claude, Jenny, Owen, Robert W., Ulrich, Alexis, Schöttker, Ben, Hoffmeister, Michael, and Brenner, Hermann
- Published
- 2017
- Full Text
- View/download PDF
37. Associations of red and processed meat intake with major molecular pathological features of colorectal cancer
- Author
-
Carr, Prudence R., Jansen, Lina, Bienert, Stefanie, Roth, Wilfried, Herpel, Esther, Kloor, Matthias, Bläker, Hendrik, Chang-Claude, Jenny, Brenner, Hermann, and Hoffmeister, Michael
- Published
- 2017
- Full Text
- View/download PDF
38. Age-specific sequence of colorectal cancer screening options in Germany: A model-based critical evaluation
- Author
-
Heisser, Thomas, Weigl, Korbinian, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
Markov processes ,Cancer diagnosis ,Cancer screening ,Colonoscopy ,Colorectal cancer ,Biological sciences - Abstract
Background The current organized screening program for colorectal cancer in Germany offers both sexes 5 annual fecal immunochemical tests (FITs) between ages 50 and 54 years, followed by a first screening colonoscopy at age 55 years if all of these FITs were negative. We sought to assess the implications of this approach for key parameters of diagnostic performance. Methods and findings Using a multistate Markov model, we estimated the expected detection rates of advanced neoplasms (advanced adenomas and cancers) and number needed to scope (NNS) to detect 1 advanced neoplasm at a first screening colonoscopy conducted at age 55 after 5 preceding negative FITs and compared them with the corresponding estimates for a first screening colonoscopy at age 55 with no preceding FIT testing. In individuals with 5 consecutive negative FITs undergoing screening colonoscopy at age 55, expected colonoscopy detection rate (NNS) was 3.7% (27) and 0.10% (1,021) for any advanced neoplasm and cancer, respectively, in men, and 2.1% (47) and 0.05% (1,880) for any advanced neoplasm and cancer, respectively, in women. These NNS values for detecting 1 advanced neoplasm are approximately 3-fold higher, and the NNS values for detecting 1 cancer are approximately 8-fold higher, than those for a first screening colonoscopy at age 55 without prior FITs. This study is limited by model simplifying assumptions and uncertainties related to input parameters. Conclusions Screening colonoscopy at age 55 after 5 consecutive negative FITs at ages 50-54, as currently offered in the German cancer early detection program, is expected to have very low positive predictive value. Our results may inform efforts to enhance the design of screening programs., Author(s): Thomas Heisser 1,2,*, Korbinian Weigl 1,3, Michael Hoffmeister 1, Hermann Brenner 1,3,4 Introduction Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the third leading cause of [...]
- Published
- 2020
- Full Text
- View/download PDF
39. Development Trajectories of Fatigue, Quality of Life, and the Ability to Work among Colorectal Cancer Patients in the First Year after Rehabilitation—First Results of the MIRANDA Study.
- Author
-
Vlaski, Tomislav, Slavic, Marija, Caspari, Reiner, Fischer, Harald, Brenner, Hermann, and Schöttker, Ben
- Subjects
CANCER patient psychology ,STATISTICS ,WORK capacity evaluation ,COLORECTAL cancer ,CANCER fatigue ,QUALITY of life ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,RESEARCH funding ,DATA analysis ,CANCER patient rehabilitation ,LONGITUDINAL method - Abstract
Simple Summary: Colorectal cancer (CRC) patients often experience fatigue, poor ability to work, and low quality of life (QoL) after therapy. We conducted a prospective study of 147 CRC patients who underwent a three-week in-patient rehabilitation clinic visit in Germany. Patients completed questionnaires at the start of rehabilitation and at regular 3-month intervals for up to a year. We found a strong correlation between fatigue and QoL, and moderate correlations between fatigue and the ability to work, as well as between QoL and the ability to work. Fatigue, QoL, and ability to work improved significantly from the start of rehabilitation to the three-month follow-up, and there was little change afterward in the first year after rehabilitation. In summary, fatigue, QoL, and the ability to work were highly interconnected in CRC patients, and all of them improved from the start of rehabilitation to the 3-month follow-up. Cancer-related fatigue, low quality of life (QoL), and low ability to work are highly prevalent among colorectal cancer (CRC) patients after tumor surgery. We aimed to analyze their intercorrelations and trajectories in the first year after in-patient rehabilitation in the German multicenter MIRANDA cohort study. Recruitment is ongoing, and we included the first 147 CRC patients in this analysis. Participants filled out questionnaires at the beginning of in-patient rehabilitation (baseline) and at 3, 6, 9, and 12 months after the baseline. The EORTC-QLQ-C30-General-Health-Status (GHS)/QoL, the FACIT-F-Fatigue Scale, and the FACIT-F-FWB-ability-to-work items were used to evaluate QoL, fatigue, and ability to work, respectively. The fatigue and QoL scales were highly correlated (r = 0.606). A moderate correlation was observed between the fatigue and ability to work scales (r = 0.487) and between the QoL and ability to work scales (r = 0.455). Compared to the baseline, a statistically significant improvement in the QoL, ability to work, and fatigue scales were observed at the 3-month follow-up (Wilcoxson signed rank test, all p < 0.0001). The three scales plateaued afterward until the 12-month follow-up. In conclusion, fatigue, QoL, and ability to work were highly interrelated, improved quickly during/after in-patient rehabilitation, and did not change much afterward in German CRC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Vitamin D Status, Cdx2 Genotype, and Colorectal Cancer Survival: Population-Based Patient Cohort.
- Author
-
Gwenzi, Tafirenyika, Schrotz-King, Petra, Schöttker, Ben, Hoffmeister, Michael, and Brenner, Hermann
- Abstract
According to recent evidence, the prognostic value of Vitamin D (VitD) status for colorectal cancer (CRC) patients might be confined to patients with the GG genotype of Cdx2, a functional polymorphism of the VitD receptor gene. We aimed to validate these findings in a cohort of CRC patients. Post-operative serum 25-hydroxyvitamin D concentration was determined by mass spectrometry and Cdx2 genotyping was performed from blood or buccal swabs using standard methods. Joint associations of VitD status and Cdx2 with overall survival (OS), CRC-specific survival (CSS), recurrence-free survival (RFS), and disease-free survival (DFS) were assessed using Cox regression. For patients with GG genotype, adjusted hazard ratios (95% confidence interval) for the associations of sufficient compared with deficient VitD were 0.63 (0.50–0.78), 0.68 (0.50–0.90), 0.66 (0.51–0.86), and 0.62 (0.50–0.77) for OS, CSS, RFS, and DFS, respectively. These associations were weaker and not statistically significant for the AA/AG genotype. Interaction between VitD status and genotype did not reach statistical significance. VitD deficiency is an independent predictor of poorer survival, particularly for the GG Cdx2 carriers, suggesting a potential role of VitD supplementation according to VitD status and genotype, which should be evaluated in randomised trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Prognostic Value of Post-Operative C-Reactive Protein-Based Inflammatory Biomarkers in Colorectal Cancer Patients: Systematic Review and Meta-Analysis.
- Author
-
Gwenzi, Tafirenyika, Zhu, Anna, Schrotz-King, Petra, Schöttker, Ben, Hoffmeister, Michael, Edelmann, Dominic, and Brenner, Hermann
- Subjects
PROGNOSIS ,TUMOR markers ,COLORECTAL cancer ,CANCER patients ,GLASGOW Coma Scale ,PROGRESSION-free survival - Abstract
Post-operative inflammation in cancer patients can be modulated by drugs and diets, but evidence on its prognostic role, which would be crucial for personalized treatment and surveillance schemes, remains rather limited. We aimed to systematically review and meta-analyse studies on the prognostic value of post-operative C-reactive protein (CRP)-based inflammatory biomarkers among patients with colorectal cancer (CRC) (PROSPERO#: CRD42022293832). PubMed, Web of Science and Cochrane databases were searched until February 2023. Studies reporting associations between post-operative CRP, Glasgow Prognostic Score (GPS) or modified Glasgow Prognostic Score (mGPS) with overall survival (OS), CRC-specific survival (CSS) and recurrence-free survival (RFS) were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the predictor-outcome associations were pooled using R-software, version 4.2. Sixteen studies (n = 6079) were included in the meta-analyses. Elevated post-operative CRP was a predictor of poor OS, CSS and RFS compared with low CRP levels [HR (95% CI): 1.72 (1.32– 2.25); 1.63 (1.30– 2.05); 2.23 (1.44– 3.47), respectively]. A unit increase in post-operative GPS predicted poor OS [HR (95% Cl): 1.31 (1.14– 1.51)]. Moreover, a unit increase in post-operative mGPS was associated with poor OS and CSS [HR (95% Cl): 1.93 (1.37– 2.72); 3.16 (1.48– 6.76), respectively]. Post-operative CRP-based inflammatory biomarkers have a significant prognostic role for patients with CRC. Prognostic value of these easy-to-obtain routine measurements thereby seems to outperform most of the much more complex blood- or tissue-based predictors in the current focus of multi-omics-based research. Future studies should validate our findings, establish optimal time for biomarker assessment and determine clinically useful cut-off values of these biomarkers for post-operative risk-stratification and treatment-response monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms
- Author
-
Tikk, Kaja, Czock, David, Haefeli, Walter E., Kopp-Schneider, Annette, and Brenner, Hermann
- Published
- 2018
- Full Text
- View/download PDF
43. Study protocol of the RaPS study: novel risk adapted prevention strategies for people with a family history of colorectal cancer
- Author
-
Tikk, Kaja, Weigl, Korbinian, Hoffmeister, Michael, Igel, Svitlana, Schwab, Matthias, Hampe, Jochen, Klug, Stefanie J., Mansmann, Ulrich, Kolligs, Frank, and Brenner, Hermann
- Published
- 2018
- Full Text
- View/download PDF
44. Quality of life and physical activity in long-term (≥5 years post-diagnosis) colorectal cancer survivors - systematic review
- Author
-
Eyl, Ruth Elisa, Xie, Kun, Koch-Gallenkamp, Lena, Brenner, Hermann, and Arndt, Volker
- Published
- 2018
- Full Text
- View/download PDF
45. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
- Author
-
Alwers, Elizabeth, Kather, Jakob N, Kloor, Matthias, Brobeil, Alexander, Tagscherer, Katrin E, Roth, Wilfried, Echle, Amelie, Amitay, Efrat L, Chang‐Claude, Jenny, Brenner, Hermann, and Hoffmeister, Michael
- Subjects
PROPORTIONAL hazards models ,PROGRESSION-free survival ,COLORECTAL cancer ,PROGNOSIS ,TUMOR-infiltrating immune cells ,CANCER patients ,CD3 antigen - Abstract
In addition to the traditional staging system in colorectal cancer (CRC), the Immunoscore® has been proposed to characterize the level of immune infiltration in tumor tissue and as a potential prognostic marker. The aim of this study was to examine and validate associations of an immune cell score analogous to the Immunoscore® with established molecular tumor markers and with CRC patient survival in a routine setting. Patients from a population‐based cohort study with available CRC tumor tissue blocks were included in this analysis. CD3+ and CD8+ tumor infiltrating lymphocytes in the tumor center and invasive margin were determined in stained tumor tissue slides. Based on the T‐cell density in each region, an immune cell score closely analogous to the concept of the Immunoscore® was calculated and tumors categorized into IS‐low, IS‐intermediate, or IS‐high. Logistic regression models were used to assess associations between clinicopathological characteristics with the immune cell score, and Cox proportional hazards models to analyze associations with cancer‐specific, relapse‐free, and overall survival. From 1,535 patients with CRC, 411 (27%) had IS‐high tumors. Microsatellite instability (MSI‐high) was strongly associated with higher immune cell score levels (p < 0.001). Stage I–III patients with IS‐high had better CRC‐specific and relapse‐free survival compared to patients with IS‐low (hazard ratio [HR] = 0.42 [0.27–0.66] and HR = 0.45 [0.31–0.67], respectively). Patients with microsatellite stable (MSS) tumors and IS‐high had better survival (HRCSS = 0.60 [0.42–0.88]) compared to MSS/IS‐low patients. In this population‐based cohort of CRC patients, the immune cell score was significantly associated with better patient survival. It was a similarly strong prognostic marker in patients with MSI‐high tumors and in the larger group of patients with MSS tumors. Additionally, this study showed that it is possible to implement an analogous immune cell score approach and validate the Immunoscore® using open source software in an academic setting. Thus, the Immunoscore® could be useful to improve the traditional staging system in colon and rectal cancer used in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Making colonoscopy‐based screening more efficient: A "gateopener" approach.
- Author
-
Heisser, Thomas, Cardoso, Rafael, Niedermaier, Tobias, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
MEDICAL screening ,EARLY detection of cancer ,COLORECTAL cancer ,CANCER prevention ,COLONOSCOPY - Abstract
Screening colonoscopy for early detection and prevention of colorectal cancer (CRC) is mostly used inefficiently. Here, we assessed the potential of an innovative approach to colonoscopy‐based screening, by use of a single, low threshold fecal immunochemical test (FIT) as a "gateopener" for screening colonoscopy. Using COSIMO, a validated simulation model, we modeled scenarios including either direct invitation to screening colonoscopy or an alternative approach involving mailing a single ("gateopener") FIT along with an invitation to colonoscopy contingent on a FIT value above a low threshold yielding a 50% positivity rate (ie, every other pretest will be positive). Under plausible assumptions on screening offer adherence, we found that such "gateopener screening" (use of screening colonoscopy contingent on a positive, low threshold gateopener FIT) approximately doubled cancer detection rates vs conventional screening. In those spared from screening colonoscopy due to a negative gateopener FIT pretest, numbers needed to screen were 10‐times higher vs those for individuals with a positive FIT, peaking in >2000 and >3800 (hypothetically) needed colonoscopies to detect one case of cancer in men and women, respectively. Gateopener screening resulted in 42%‐51% and 59%‐65% more prevented CRC cases and deaths, respectively. In summary, by directing colonoscopy capacities to those most likely to benefit, offering screening colonoscopy contingent on a "gateopener" low‐threshold FIT would substantially enhance efficiency of colonoscopy screening. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases.
- Author
-
Ugai, Tomotaka, Akimoto, Naohiko, Haruki, Koichiro, Harrison, Tabitha A., Cao, Yin, Qu, Conghui, Chan, Andrew T., Campbell, Peter T., Berndt, Sonja I., Buchanan, Daniel D., Cross, Amanda J., Diergaarde, Brenda, Gallinger, Steven J., Gunter, Marc J., Harlid, Sophia, Hidaka, Akihisa, Hoffmeister, Michael, Brenner, Hermann, Chang-Claude, Jenny, and Hsu, Li
- Subjects
COLORECTAL cancer ,COLON tumors ,SIGMOID colon ,CANCER patients ,COLON cancer - Abstract
Background: The pathogenic effect of colorectal tumor molecular features may be influenced by several factors, including those related to microbiota, inflammation, metabolism, and epigenetics, which may change along colorectal segments. We hypothesized that the prognostic association of colon cancer location might differ by tumor molecular characteristics. Methods: Utilizing a consortium dataset of 13,101 colorectal cancer cases, including 2994 early-onset cases, we conducted survival analyses of detailed tumor location stratified by statuses of microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and KRAS and BRAF oncogenic mutation. Results: There was a statistically significant trend for better colon cancer-specific survival in relation to tumor location from the cecum to sigmoid colon (P
trend = 0.002), excluding the rectum. The prognostic association of colon location differed by MSI status (Pinteraction = 0.001). Non-MSI-high tumors exhibited the cecum-to-sigmoid trend for better colon cancer-specific survival [Ptrend < 0.001; multivariable hazard ratio (HR) for the sigmoid colon (vs. cecum), 0.80; 95% confidence interval (CI) 0.70–0.92], whereas MSI-high tumors demonstrated a suggestive cecum-to-sigmoid trend for worse survival (Ptrend = 0.020; the corresponding HR, 2.13; 95% CI 1.15–3.92). The prognostic association of colon tumor location also differed by CIMP status (Pinteraction = 0.003) but not significantly by age, stage, or other features. Furthermore, MSI-high status was a favorable prognostic indicator in all stages. Conclusions: Both detailed colonic location and tumor molecular features need to be accounted for colon cancer prognostication to advance precision medicine. Our study indicates the important role of large-scale studies to robustly examine detailed colonic subsites in molecular oncology research. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
48. Persisting Deficits in Health-Related Quality of Life of Colorectal Cancer Survivors 14–24 Years Post-Diagnosis: A Population-Based Study.
- Author
-
Thong, Melissa S. Y., Doege, Daniela, Weißer, Linda, Koch-Gallenkamp, Lena, Jansen, Lina, Bertram, Heike, Eberle, Andrea, Holleczek, Bernd, Nennecke, Alice, Waldmann, Annika, Zeissig, Sylke Ruth, Brenner, Hermann, and Arndt, Volker
- Subjects
QUALITY of life ,COLON cancer ,CANCER patients ,INTESTINAL diseases ,POPULATION-based case control - Abstract
(1) Background: The health-related quality of life (HRQOL) of colorectal cancer (CRC) survivors >10 years post-diagnosis is understudied. We aimed to compare the HRQOL of CRC survivors 14–24 years post-diagnosis to that of age- and sex-matched non-cancer controls, stratified by demographic and clinical factors. (2) Methods: We used data from 506 long-term CRC survivors and 1489 controls recruited from German population-based multi-regional studies. HRQOL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (EORTC QLQ-C30) questionnaire. We estimated differences in the HRQOL of CRC survivors and controls with multiple regression, adjusted for age at survey, sex, and education, where appropriate. (3) Results: CRC survivors reported poorer social functioning but better health status/QOL than controls. CRC survivors, in general, had higher levels of symptom burden, and in particular diarrhea and constipation, regardless of demographic or clinical factors. In stratified analyses, HRQOL differed by age, sex, cancer type, and having a permanent stoma. (4) Conclusions: Although CRC survivors may have a comparable health status/QOL to controls 14–24 years after diagnosis, they still live with persistent bowel dysfunction that can negatively impact aspects of functioning. Healthcare providers should provide timely and adapted follow-up care to ameliorate potential long-term suffering. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Impact of Reducing Intake of Red and Processed Meat on Colorectal Cancer Incidence in Germany 2020 to 2050—A Simulation Study.
- Author
-
Niedermaier, Tobias, Gredner, Thomas, Hoffmeister, Michael, Mons, Ute, and Brenner, Hermann
- Abstract
Background: According to the International Agency for Research on Cancer (IARC), there is sufficient evidence for the carcinogenicity of processed meat consumption in humans, specifically regarding colorectal cancer (CRC) risk. Evidence for the carcinogenicity of red meat consumption is more limited but points in the same direction. Methods: A macro-simulation approach was used to calculate age- and sex-specific potential impact fractions in a 30-year period (2020–2050). Aims: We estimated numbers and proportions of future CRC cases preventable under different scenarios of reducing the intake of processed and red meat in the German population. Results: Eliminating processed meat intake could reduce the burden of CRC by approximately 205,000 cases in Germany (9.6%) in 2020–2050, 2/3 among males (145,000) and 1/3 among females (60,000). Without red meat intake, approximately 63,000 CRC cases could be avoided (2.9%), 39,000 among males and 24,000 among females. Reductions in the mean consumption of both processed and red meat by one or two servings (each 11 or 22 g) per day would be expected to reduce CRC case numbers by 68,000 (3.1%) and 140,000 (6.5%), respectively. Conclusion: A reduction in red and processed meat intake might substantially reduce the incidence of CRC in Germany. The means of achieving such a reduction might include price and taxation policies, food labeling, and clearer risk communication aiming to reduce individual intake. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Physical activity, polygenic risk score, and colorectal cancer risk.
- Author
-
Chen, Xuechen, Guo, Feng, Chang‐Claude, Jenny, Hoffmeister, Michael, and Brenner, Hermann
- Subjects
MONOGENIC & polygenic inheritance (Genetics) ,DISEASE risk factors ,COLORECTAL cancer ,PHYSICAL activity ,GENETIC variation - Abstract
Introduction: Whether and to what extent the relationship between physical activity (PA) and colorectal cancer (CRC) differs according to CRC‐related genetic risk remains to be determined, and no studies to date have quantified how much genetically determined risk could be compensated for with active exercise. Methods: Genetic risk was quantified by a polygenic risk score (PRS) summarizing the estimated effect of 140 CRC‐associated genetic variants. Associations of PA with CRC risk were estimated by multivariable logistic regression across PRS levels. We also compared the impact of PA and specific PA types to the PRS using "genetic risk equivalent (GRE)", a novel approach to enhance effective risk communication. Results: Among 5058 CRC patients and 4134 controls, we observed no significant association between overall PA level in quartiles and CRC risk. However, the highest versus lowest lifetime leisure time physical activity (LTPA) was associated with a 13% lower CRC risk [odds ratio 0.87, 95% confidence interval (CI) 0.77–1.00] independent of PRS levels (adjusted p value for interaction = 0.18). This effect was equivalent to the effect of having 11 percentiles lower PRS (GRE −10.6, 95% CI −20.7 to −0.6). The GRE (95% CI) for the highest lifetime sports tertile was −23.0 (−33.9 to −12.0). Conclusions: LTPA was inversely associated with CRC risk irrespective of polygenic risk for CRC, which reinforces the importance of LTPA in CRC prevention among the general population. Adequate sports activity can compensate for a large share of polygenic risk for CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.